ARCHIVES

Pfizer’s Inlyta Gives FDA a Teaching Moment: Not All PFS Advantages Are Created Equal

This article is from The Cancer Letter archive.

Vol. 37 No. 46 | December 16, 2011

Download PDF Visit The Full Archive

Related Articles

Radiotherapy Plus Cetuximab May Control Head/Neck Cancer

November 26, 2010

Elderly and Younger Patients Have Similar Outcomes Following Radioembolization

July 26, 2013

Study Suggests Surveillance Colonoscopies Overperformed

August 27, 2004

Study Finds Gene Expression Test Predicts Stage I or II Recurrence

August 30, 2013

Study: Ibrutinib Lowers IgM, Bone Marrow Disease Burden

July 26, 2013

NCI To Slow New Center Development To Assure Funding For Existing Commitments, King Says

February 14, 1975